ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer
Public ClinicalTrials.gov record NCT01825603. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial studies the side effects and best dose of ADH-1 when given together with gemcitabine hydrochloride and cisplatin in treating patients with pancreatic or biliary tract cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or spread to other parts of the body (metastatic) and cannot be removed by surgery. ADH-1 may stop the growth of cancer cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ADH-1 together with gemcitabine hydrochloride and cisplatin may kill more tumor cells.
Study identification
- NCT ID
- NCT01825603
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 17 participants
Conditions and interventions
Conditions
- Ampulla of Vater Adenocarcinoma
- Gallbladder Adenocarcinoma
- Metastatic Pancreatic Adenocarcinoma
- Pancreatic Adenocarcinoma
- Stage III Ampulla of Vater Cancer
- Stage III Intrahepatic Cholangiocarcinoma
- Stage III Pancreatic Cancer
- Stage IIIA Gallbladder Cancer
- Stage IIIA Hilar Cholangiocarcinoma
- Stage IIIB Gallbladder Cancer
- Stage IIIB Hilar Cholangiocarcinoma
- Stage IV Ampulla of Vater Cancer
- Stage IVA Gallbladder Cancer
- Stage IVA Hilar Cholangiocarcinoma
- Stage IVA Intrahepatic Cholangiocarcinoma
- Stage IVA Pancreatic Cancer
- Stage IVB Gallbladder Cancer
- Stage IVB Hilar Cholangiocarcinoma
- Stage IVB Intrahepatic Cholangiocarcinoma
- Stage IVB Pancreatic Cancer
Interventions
- ADH-1 Drug
- Cisplatin Drug
- Gemcitabine Hydrochloride Drug
- Laboratory Biomarker Analysis Other
Drug · Other
Eligibility (public fields only)
- Age range
- 19 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 8, 2013
- Primary completion
- May 31, 2017
- Completion
- May 31, 2017
- Last update posted
- Dec 27, 2023
2013 – 2017
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01825603, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 27, 2023 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01825603 live on ClinicalTrials.gov.